TMS and Schizophrenia
Around 1% of the population develop schizophrenia (NICE 2008), and the estimated total societal cost of schizophrenia has been estimated at almost £7 billion per year in England alone (Mangalore & Knapp 2006). Neurologically, it is characterised by hypofunctioning of the frontal lobes (Weinberger et al. 1988) and widespread grey matter deficits (Zipursky et al. 1992). Impaired memory, attention and motor skills (Heinrichs and Zakzanis 1998) are specific indicators, and diagnosis is currently based on meeting certain criteria. TMS can be used to elucidate the pathophysiological mechanisms of schizophrenia.
Repetitive TMS has been proposed as a treatment for the negative symptoms of schizophrenia. A recent systematic meta-review, for example, stated that high quality evidence suggested a short-term, medium to large treatment effect for auditory hallucinations associated with schizophrenia (Matheson et al. 2010). Another recent study found that theta burst stimulation of the cerebellar vermis is safe and well-tolerated, while offering the potential to modulate affect, emotion and cognition in schizophrenia (Demirtas-Tatlidede et al. 2010).
Several studies have uncovered evidence for reduced plasticity in the brains of certain schizophrenic patients, it is possible that this reduced plasticity can explain medication resistance and may be the reason that treatment with rTMS has some success.
References
- Demirtas-Tatlidede et al., Schizophr Res, 2010.
- Heinrichs and Zakzanis, Neuropsychology, 1998.
- Mangalore & Knapp. PSSRU. 2006.
- Matheson et al. Schizophr Res. 2010.
- NICE Clinical Guideline 82. 2009.
- Weinberger et al., Ann N Y Acad Sci, 1988.
- Zipursky et al., Archives of General Psychiatry, 1992.